ANAPTYSBIO, INC

Clinical-stage biotech developing immunology therapies for autoimmune and inflammatory diseases.

ANAB | US

Overview

Corporate Details

ISIN(s):: US0327241065
LEI:
Country:: United States of America
Address:: 10770 WATERIDGE CIRCLE, SUITE 210, 92121 SAN DIEGO
Website:: https://www.anaptysbio.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AnaptysBio, Inc. is a clinical-stage biotechnology company that develops innovative immunology therapeutics for autoimmune and inflammatory diseases. The company's pipeline includes rosnilimab, a pathogenic T cell depleter in Phase 2b trials for rheumatoid arthritis, and ANB033, a CD122 antagonist. AnaptysBio has announced plans to separate its biopharmaceutical operations from its royalty assets into two independent, publicly traded companies by year-end 2026 to align with different investor strategies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ANAPTYSBIO, INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ANAPTYSBIO, INC

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ANAPTYSBIO, INC via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Kidswell Bio Corporation Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.	Japan	4584
Kinarus Therapeutics Holding AG A specialty pharma firm developing and selling medicines for rare and specialty diseases.	Switzerland	KNRS
Kiniksa Pharmaceuticals International, plc Develops and commercializes immune-modulating therapies for debilitating diseases with unmet needs.	United States of America	KNSA
KIORA PHARMACEUTICALS INC Developing advanced small molecule therapies for vision-threatening retinal diseases.	United States of America	KPRX
KISSEI PHARMACEUTICAL CO.,LTD. Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.	Japan	4547
Klaria Pharma Holding AB Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.	Sweden	KLAR
Klotho Neurosciences, Inc. Advancing gene and cell therapies for neurodegenerative disorders, cancer, and chronic diseases.	United States of America	KLTO
KOA SHOJI HOLDINGS CO.,LTD. Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.	Japan	9273
KOBAYASHI PHARMACEUTICAL CO.,LTD. Manufactures OTC pharma, personal care, and household goods for niche consumer markets.	Japan	4967
Kodiak Sciences Inc. Developing durable biologics to treat high-prevalence retinal diseases and prevent blindness.	United States of America	KOD